CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
NCT06258447
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
Concentrated autologous bone marrow mononuclear cells (ABM MNC) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ischemic Heart Failure
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 21 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- BioCardia, Inc.
- Last updated on ClinicalTrials.gov
- February 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Morton Plant Hospital - BayCare · Clearwater, FL
Georgia · 1
- Emory University · Atlanta, GA
Michigan · 1
- Henry Ford Hospital · Detroit, MI
Wisconsin · 1
- University of Wisconsin-Division of Cardiovascular Medicine · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.